Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JACC Heart Fail
Auteurs principaux: Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene
Format: Artigo
Langue:Inglês
Publié: by the American College of Cardiology Foundation. Published by Elsevier. 2020
Sujets:
Focus Issue: Angiotensin-Neprilysin Inhibition: Novel Insights
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://ncbi.nlm.nih.gov/pubmed/32641226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2020.05.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires